<DOC>
	<DOCNO>NCT00642460</DOCNO>
	<brief_summary>This study evaluate efficacy safety RoActemra/Actemra ( tocilizumab ) patient active systemic juvenile idiopathic arthritis ( sJIA ) inadequate clinical response NSAIDs corticosteroid . In Part I study patient randomize 2:1 receive iv infusion RoActemra/Actemra ( 8mg/kg iv patient &gt; =30kg , 12mg/kg patient &lt; 30kg ) placebo , every 2 week . Stable NSAIDs methotrexate continue throughout . After 12 week double-blind treatment , patient option enter Part II study receive open-label treatment RoActemra/Actemra 92 week , follow 3-year continuation study Part III , patient meet specific criterion , optional alternative dosing schedule decrease study drug administration frequency introduce . Anticipated time study treatment 5 year .</brief_summary>
	<brief_title>A Study RoActemra/Actemra ( Tocilizumab ) Patients With Active Systemic Juvenile Idiopathic Arthritis ( JIA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Anti-Inflammatory Agents , Non-Steroidal</mesh_term>
	<criteria>Patients age 217 year age Systemic juvenile idiopathic arthritis &gt; = 6 month persistent activity Presence active disease ( &gt; =5 active joint , &gt; =2 active joint + fever + steroid ) Inadequate clinical response nonsteroidal antiinflammatory drug ( NSAIDs ) corticosteroid due toxicity lack efficacy Wheelchairbound bedridden Any autoimmune , rheumatic disease overlap syndrome systemic juvenile idiopathic arthritis Intravenous longacting corticosteroid intraarticular corticosteroid within 4 week baseline , throughout study Diseasemodifying antirheumatic drug ( DMARDs ) , methotrexate Previous treatment tocilizumab</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>